Gene Therapy Targeting Connexin-43 Shows Promise for Treating Inherited Heart Disease in Young Athletes
Key Insights
UC San Diego researchers discovered that restoring connexin-43 (search) protein through gene therapy more than doubled lifespan and dramatically improved heart function in mouse models of arrhythmogenic cardiomyopathy (search).
The therapy showed effectiveness across multiple genetic forms of ACM by addressing a common downstream defect, potentially offering a universal treatment approach for this leading cause of sudden cardiac death (search) in young athletes.
LEXEO Therapeutics has acquired the connexin-43 (search) program for commercial development, with preclinical studies underway to evaluate safety and therapeutic potential.
A University of California San Diego-led research team has achieved a significant breakthrough in treating arrhythmogenic cardiomyopathy (search) (ACM), a deadly inherited heart condition that disproportionately affects young athletes. The study, published January 26, 2026 in Circulation: Heart Failure (search), demonstrates that gene therapy targeting connexin-43 (search) protein can dramatically improve heart function and extend survival across multiple genetic forms of the disease.
Revolutionary Approach to a Deadly Condition
ACM impedes the heart from pumping blood effectively and represents a leading cause of sudden cardiac death (search) in young people, particularly athletes who may unknowingly push their hearts to dangerous limits during intense exercise. "At first glance, you would think these individuals are very healthy as they are active and exercising regularly, but unfortunately they're born with genetic mistakes that weaken the glue holding heart muscle cells together," explained senior corresponding author Farah Sheikh, professor of medicine at UC San Diego School of Medicine.
The condition occurs when mutations affect genes encoding desmosomes (search) - proteins that anchor heart cells together. Over time, weakened cells are replaced by scar tissue, making the heart increasingly vulnerable to stress from each heartbeat, potentially leading to sudden death or heart failure (search).
Breakthrough Results in Preclinical Studies
Rather than targeting specific genetic mutations, the researchers focused on restoring connexin-43 (search), a protein commonly deficient across all forms of ACM. This protein is essential for maintaining electrical conductivity in heart muscle and reestablishing heart rhythm, though it hadn't previously been shown to repair muscle tissue itself.
The gene therapy approach yielded remarkable results in mouse models of arrhythmogenic cardiomyopathy (search):
- More than doubled lifespan
- Improved the heart's ability to pump blood and prevented heart enlargement
- Led to dramatic reduction in heart arrhythmias and greater electrical conductivity
- Restored desmosome proteins that keep muscle cells connected and corrected structural defects in heart tissue
Notably, these positive outcomes were observed even in mice that received gene therapy during advanced stages of disease progression.
Human Cell Validation and Novel Mechanism
The team validated their findings using human heart muscle cells derived from induced pluripotent stem cells provided by ACM patients. Similar to the mouse model results, restoring connexin-43 (search) helped heart cells maintain integrity, beat more normally, and regain proteins necessary for strong cellular connections.
The researchers made an unexpected discovery about connexin-43 (search)'s mechanism of action. "What surprised us was that connexin-43 moves into the nucleus," said Sheikh. "That finding suggested it may help reprogram heart muscle cells to strengthen their mechanical connections and improve heart function. Connexin-43 might not just be keeping the cell together electrically, but structurally as well."
This nuclear translocation appears to influence gene transcription, stimulating production of key mechanical junction proteins - a finding that could have major implications for ACM treatment.
Universal Treatment Potential
The approach addresses a critical unmet medical need in ACM treatment. While Sheikh's previous research led to development of a gene therapy targeting plakophilin-2 (search) (currently in Phase 1/2 clinical trials), ACM can arise from mutations in multiple desmosomal genes, some too large for current gene therapy approaches.
"We found that defects in these cellular connections could be corrected using connexin-43 (search) gene therapy," said Sheikh. "That gave us confidence that this approach may have broader therapeutic potential across multiple genetic forms of the disease, as it is known to be a common downstream defect. Conceptually, it offers a way to help glue heart muscle cells back together again, and we're really encouraged by that."
Commercial Development and Future Applications
LEXEO Therapeutics has acquired the connexin-43 (search) program and initiated commercial development, with preclinical studies underway to further evaluate safety and therapeutic potential. The therapy's potential extends beyond ACM, as connexin-43 is often missing in heart muscle cells of patients with other forms of cardiomyopathy (search) and heart failure (search).
"We want to understand how broadly this therapy can be applied across heart diseases and identify the window in which treatment has the greatest chance of having a positive outcome," Sheikh noted.
The research was supported by grants from the National Institutes of Health, California Institute of Regenerative Medicine, and U.S. Department of Defense, representing a collaborative effort involving researchers from multiple institutions including Stanford University, McMaster University, University of Illinois Chicago, and UC San Francisco.